Skip to contentO
Oncotelic Therapeutics, Inc.
O
OTLCOncotelic Therapeutics, Inc. Q2 2021 · 10-Q
Revenue—
Net Income-$3.23M-$3.23MN/M vs Q2 2020 EPS Diluted-$0.01-$0.01N/M vs Q2 2020 Operating Income-$3,764,212N/M Operating Cash Flowderived-$1,214,417N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oncotelic Therapeutics, Inc. · CIK 908259 · Engraved from SEC EDGAR
ended Jun 30, 2021 · filed Aug 20, 2021 · 51 d after period end